News & Events

Biotec Pharmacon awarded grant from Research Council of Norway to develop next-generation wound product

Biotec Pharmacon awarded grant from Research Council of Norway to develop next-generation wound product

Tromsø, Norway, 4 February 2019 – Biotec Pharmacon (OSE: Biotec) announces today that its subsidiary Biotec BetaGlucans has been awarded up to NOK 8 million in a grant by the Research Council of Norway for a project titled “Bioactive wound healing dressing with beta-glucan for treatment of hard-to-heal wounds”. The project is to be supported over 4 years.

The grant has been awarded from the User-driven Research-based Innovation Programme (BIA), and the focus of the project will be to develop first of its kind bioactive gel-forming fibre dressings. These dressings will contain soluble beta-glucan (SBG®) for the treatment of hard-to-heal wounds by re-activating the healing process.

The project aims to develop new and cost-effective wound healing devices for the treatment of large hard-to-heal wounds, exuding wounds (burns and ulcers), donor-site wounds, and wounds on mucosal surfaces.

Established in 2006, the BIA programme is one of the largest programmes at the Research Council and is a key partner for Norwegian trade and industry. This broad-based programme supports high-quality R&D projects with good business and socio-economic potential.

The award is subject to successful contract negotiations between the parties.

Christian Jørgensen, CEO, said:

“We are pleased to have been awarded this grant, which serves as a great testament to the hard work being done at Biotec BetaGlucans. It will help us develop a broader set of treatments for the many people suffering from different types of hard-to-heal wounds.”


About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website:

About Biotec BetaGlucans

BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae

The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.

Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.

For more information, please visit:

Issued for and on behalf of Biotec Pharmacon by Instinctif Partners.
For more information please contact


back to news